What is the appropriate management for a patient with low thyroid‑stimulating hormone (TSH) and normal free thyroxine (FT4)?

Management of Low TSH with Normal FT4

Confirm the diagnosis by repeating thyroid function tests in 2-3 months, as this pattern represents subclinical hyperthyroidism that requires verification before any intervention, and assess the degree of TSH suppression to guide treatment decisions.1, 2

Initial Diagnostic Approach

Confirm and Classify the Finding

• Repeat testing is essential because transient TSH suppression occurs frequently from non-thyroidal causes including medications (dopamine, glucocorticoids, dobutamine), acute illness (euthyroid sick syndrome), pregnancy (first trimester), or recent treatment for hyperthyroidism.1

• Classify severity based on TSH level:3

  • Grade I (mild): TSH 0.1-0.4 mIU/L with normal FT4 and FT3
  • Grade II (severe): TSH <0.1 mIU/L with normal FT4 and FT3

• Undetectable TSH (<0.01 mIU/L) is rare in non-thyroidal illness unless the patient is receiving high-dose glucocorticoids or dopamine; this finding strongly suggests true thyroid disease.1

Rule Out Non-Thyroidal Causes

• Check medication history for levothyroxine overtreatment (iatrogenic/factitial hyperthyroidism), which is a common cause.2

• Exclude pituitary/hypothalamic disease: In central hypothyroidism, FT4 is typically low or low-normal (in the lower part of the reference range), not mid-to-high normal as seen in subclinical hyperthyroidism.1

• Consider timing: Normal pregnancy causes physiologic TSH suppression in the first trimester.1

Investigate the Underlying Cause

Once confirmed as persistent subclinical hyperthyroidism:

• Order thyroid antibodies (TSH receptor antibodies for Graves' disease) and thyroid ultrasound to differentiate between Graves' disease and toxic nodular goiter, the two most common endogenous causes.2

• Obtain radioactive iodine uptake scan if nodular disease is suspected to determine if nodules are functioning.2

Assess for Complications

Screen for cardiovascular and skeletal complications, particularly in older patients:2

• Atrial fibrillation risk: Check ECG, especially in patients >65 years, as subclinical hyperthyroidism increases AF risk
• Bone density: Consider DEXA scan in postmenopausal women and older men, as TSH suppression accelerates bone loss
• Cardiac function: Assess for symptoms of heart failure or angina

Treatment Decision Algorithm

Treat if:2

• Age >65 years regardless of TSH level or symptoms
• TSH <0.1 mIU/L (Grade II) at any age
• Presence of comorbidities: osteoporosis, atrial fibrillation, cardiovascular disease, or heart failure symptoms
• Persistent suppression on repeat testing after 2-3 months

Monitor without treatment if:2, 3

• Age <65 years AND

• TSH 0.1-0.4 mIU/L (Grade I) AND

• No cardiovascular or skeletal complications AND

• Asymptomatic

• Repeat thyroid function tests every 6-12 months with clinical reassessment

Treatment Options

When treatment is indicated:2

• Radioactive iodine ablation: First-line for toxic nodular goiter and often for Graves' disease in older patients
• Antithyroid drugs (methimazole): Option for Graves' disease, particularly in younger patients
• Surgery: Reserved for large goiters with compressive symptoms or when other treatments contraindicated

Critical Pitfalls to Avoid

• Do not treat based on a single abnormal TSH value without confirmation, as transient suppression is common and treatment may be unnecessary.1, 2

• Do not assume all low TSH represents thyroid disease—the differential diagnosis is broad, and FT4 level helps distinguish true subclinical hyperthyroidism (high-normal FT4) from non-thyroidal illness (low-normal FT4).1

• Do not ignore age in treatment decisions—the threshold for treatment is lower in elderly patients due to significantly higher cardiovascular and bone complications.2

• Do not overlook medication-induced TSH suppression, particularly levothyroxine overtreatment, which simply requires dose adjustment rather than additional interventions.2